IBOV 167,921.80 ▼ 0.75% IPC MEX 69,779.20 ▼ 0.01% MERVAL 2,848,945 — — USD/BRL5.44▼ 0.03% USD/MXN18.54▼ 1.32% USD/CLP974.93▼ 1.92% USD/COP3,224▼ 0.14% USD/PEN3.46▼ 0.20% USD/ARS1,544▲ 0.52% USD/UYU40.19▼ 0.01% USD/PYG5,915▼ 0.84% USD/BOB12.00▼ 0.58% USD/DOP60.16▼ 0.43% USD/CRC449.70▼ 0.39% USD/GTQ7.64— 0.00% USD/HNL26.89▲ 0.02% USD/NIO36.62— 0.00% USD/VES887.35▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69▼ 0.19% USD/TTD6.65▼ 0.91% EUR/BRL6.09▲ 1.24% BRENT 109.58 ▼ 5.38% WTI 100.12 ▼ 1.61% IRON ORE 161.91 — — COPPER 6.65 ▲ 2.24% GOLD 4,073 ▲ 0.85% SILVER 54.49 ▲ 0.70% SOY 1,250 ▲ 0.70% CORN 450.25 ▼ 1.04% WHEAT 614.75 ▼ 0.20% COFFEE 294.35 ▼ 2.19% SUGAR 19.26 ▲ 0.84% ORANGE JUICE 143.20 ▲ 5.45% COTTON 77.90 ▼ 1.47% COCOA 5,581 ▲ 1.66% BEEF 230.73 ▲ 0.33% CATTLE 346.40 ▼ 1.00% LITHIUM 62.43 ▲ 1.89% PETR4 53.31 ▼ 1.06% VALE3 62.88 ▼ 2.33% ITUB4 41.42 ▼ 0.67% BBDC4 15.69 ▼ 1.63% ABEV3 15.40 ▲ 0.20% BBAS3 17.59 ▲ 0.69% B3SA3 15.27 ▲ 1.33% WEGE3 45.78 ▲ 2.81% PRIO3 69.21 ▼ 2.71% SUZB3 47.14 ▼ 0.55% RENT3 31.14 ▼ 1.67% AZZA3 16.72 ▲ 1.15% CSAN3 2.69 ▼ 2.89% RAIZ4 0.34 — 0.00% PCAR3 2.22 ▼ 3.48% GMAT3 3.74 ▲ 2.19% PSSA3 47.75 ▼ 0.89% CVCB3 0.98 — 0.00% POSI3 3.56 ▼ 0.84% SLCE3 16.97 ▼ 2.75% NATU3 5.68 ▼ 3.89% BRKM5 3.80 ▲ 19.50% RANI3 7.34 ▼ 0.54% CSNA3 4.76 ▼ 4.99% IBOV 167,921.80 ▼ 0.75% IPC MEX 69,779.20 ▼ 0.01% MERVAL 2,848,945 — — USD/BRL 5.34 ▼ 1.32% USD/MXN 18.69 ▲ 0.62% USD/CLP 983.47 ▼ 0.57% USD/COP 3,149 ▲ 3.06% USD/PEN 3.45 ▲ 0.17% USD/ARS 1,537 ▼ 0.28% USD/UYU 40.21 ▲ 3.57% USD/PYG 5,803 ▲ 3.78% USD/BOB 11.97 ▲ 4.93% USD/DOP 60.54 ▲ 1.83% USD/CRC 451.24 ▲ 2.13% USD/GTQ 7.64 ▲ 3.23% USD/HNL 26.87 ▲ 3.37% USD/NIO 36.62 ▲ 2.81% USD/VES 885.08 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 2.63% USD/TTD 6.71 ▲ 2.07% EUR/BRL 5.95 ▲ 7.53% BRENT 109.58 ▼ 5.38% WTI 100.12 ▼ 1.61% IRON ORE 161.91 — — COPPER 6.65 ▲ 2.24% GOLD 4,073 ▲ 0.85% SILVER 54.49 ▲ 0.70% SOY 1,250 ▲ 0.70% CORN 450.25 ▼ 1.04% WHEAT 614.75 ▼ 0.20% COFFEE 294.35 ▼ 2.19% SUGAR 19.26 ▲ 0.84% ORANGE JUICE 143.20 ▲ 5.45% COTTON 77.90 ▼ 1.47% COCOA 5,581 ▲ 1.66% BEEF 230.73 ▲ 0.33% CATTLE 346.40 ▼ 1.00% LITHIUM 62.43 ▲ 1.89% PETR4 53.31 ▼ 1.06% VALE3 62.88 ▼ 2.33% ITUB4 41.42 ▼ 0.67% BBDC4 15.69 ▼ 1.63% ABEV3 15.40 ▲ 0.20% BBAS3 17.59 ▲ 0.69% B3SA3 15.27 ▲ 1.33% WEGE3 45.78 ▲ 2.81% PRIO3 69.21 ▼ 2.71% SUZB3 47.14 ▼ 0.55% RENT3 31.14 ▼ 1.67% AZZA3 16.72 ▲ 1.15% CSAN3 2.69 ▼ 2.89% RAIZ4 0.34 — 0.00% PCAR3 2.22 ▼ 3.48% GMAT3 3.74 ▲ 2.19% PSSA3 47.75 ▼ 0.89% CVCB3 0.98 — 0.00% POSI3 3.56 ▼ 0.84% SLCE3 16.97 ▼ 2.75% NATU3 5.68 ▼ 3.89% BRKM5 3.80 ▲ 19.50% RANI3 7.34 ▼ 0.54% CSNA3 4.76 ▼ 4.99%
since 2009
Monday, November 2, 2026

Covid-19 Brazil

How Proposed Brazilian Nasal Spray Vaccine Against Covid-19 Could Work

By · January 18, 2021 · 2 min read

RIO DE JANEIRO, BRAZIL – A vaccine with no needle, no pain and no crying – this is the proposal of Brazilian scientists developing a nasal spray immunizer against the novel coronavirus. The vaccine, which has been under development since April 2020, has already shown good results in tests with mice and should be approved by the end of this year (if all goes well).

A vaccine with no needle, no pain and no crying - this is the proposal of Brazilian scientists developing a nasal spray immunizer against the novel coronavirus.
A vaccine with no needle, no pain and no crying – this is the proposal of Brazilian scientists developing a nasal spray immunizer against the novel coronavirus.
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

The concept of developing a spray vaccine was no accident. According to the head of research Jorge Elias Kalil Filho, the goal of the immunizer is to attack the virus at its gateway to the human body: the nasal mucosa.

To this end, researchers identified the most important targets of the immune response. “We see a better performance in a fragment of the spicule protein which is called the binding agent to the receptor [RBD], which is precisely the portion of the spicule protein that binds to the human cell receptor called ACE-2”, he says.

To develop the vaccine, 220 blood samples from people who recovered from the Covid-19 respiratory infection were investigated to understand which fragments of the coronavirus produced an immune response of T cells (responsible for the body’s defense) and which recognized and killed the infected cells.

Based on the studies, the scientists designed a hybrid artificial molecule with T-cell and RBD induction fragments. To carry this “blend” to the immune system, nanoparticles were developed in the laboratory.

The researchers’ goal is to develop a vaccine capable of making the human body produce the cellular and defense immune response, as well as generate a memory cell that will prevent the coronavirus from developing and reproducing after an infection – this is because, up to now, the memory created by the disease itself has not been proven to be lasting.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.